Combination Treatment of Miriplratin-iodized-oil Suspension Iinjection and Radiofrequency Ablation in Hepatocellular Carcinoma

2017 Fiscal Year Final Research Report

• Project/Area Number: 25461876
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Radiation science
• Research Institution: Mie University
• Principal Investigator: YAMANAKA Takashi 三重大学, 医学系研究科, 助教 (80642074)
• Co-Investigator(Kenkyū-buntansha): 馬場 康貴 鹿児島大学, 医学部・歯学部附属病院, 講師 (00315409) ; 穴井 洋 奈良県立医科大学, 医学部, 非常勤講師 (00322371) ; 山門 亨一郎 兵庫医科大学, 医学部, 教授 (20263022) ; 高木 治行 三重大学, 医学部, 助教 (30378377) ; 中塚 豊真 三重大学, 医学部附属病院, 講師 (70303740)
• Project Period (FY): 2013-04-01 – 2018-03-31
• Keywords: 肝細胞癌 / ミリプラチン / ラジオ波凝固療法

Outline of Final Research Achievements

To prospectively evaluate the safety and outcomes of combination treatment of miriplratin-iodized-oil suspension injection and radiofrequency ablation in hepatocellular carcinoma, local tumor progression at 2-year,adverse event, feasibility, initial response, local tumor progression on tumor basis at 2-year, overall survival rate at 2-year,and progression free survival rate at 2-year were evaluated.
local tumor progression at 2-year was 6.2% (1.1%-18.2%）. Feasibility was 100%（37/37）. Initial response was 93.8％（30/32）. local tumor progression on tumor basis at 2-year was 5.6%（1.0%-16.3%). progression free survival rate at 2-year was 84.4%（71.9%-96.9%）.

Free Research Field

放射線科